Urology | Home | MIMS Malaysia

Abiraterone provides better HRQoL than enzalutamide for mCRPC

4 days ago

Treatment with abiraterone leads to fewer health-related quality of life (HRQoL) and mental health issues than enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC), a recent study has found.

Preoperative neutrophil-to-lymphocyte ratio predicts outcomes in testicular cancer

Tristan Manalac, 4 days ago

High neutrophil-to-lymphocyte ratio before radical orchidectomy appears to be predictive of worse outcomes in testicular cancer patients, according to a recent Singapore study.

Educational intervention, overprescription reduce opioid use after pelvic floor surgery

15 May 2019

Overprescription of opioids after pelvic floor surgery and a provider education intervention have led to a substantial decrease in opioid prescribing without changing patient satisfaction with pain control, a recent study has found.

Opioid use may be reduced without increasing pain in outpatient paediatric surgery

15 May 2019

A recent study suggests the feasibility of reducing opioid prescriptions without increasing pain scores in outpatient paediatric surgical practice. In addition, prescribing practices among physicians may contribute more to opioid consumption than actual pain patterns.

Wearable device tells children when to pee

Tristan Manalac, 07 May 2019

SENS-U, a small and wireless wearable sensor, accurately monitors natural bladder filling during activities of daily living and can notify children when the bladder is almost full, according to a new study.

Uroselective α1A-AR antagonist: A promising agent for the management of BPH

15 Mar 2019

At the Eisai-sponsored tea symposium during the 27th Malaysian Urological Conference at Shangri-La Kuala Lumpur, Professor Osamu Yokoyama highlighted the advantages of silodosin (Urief®, Eisai Inc.) in relieving lower urinary tract symptoms associated with benign prostate hyperplasia.

Nocturia: An inside view on key causes and principles of management

02 Nov 2017

Nocturia is the most prevalent of the lower urinary tract symptoms (LUTS) and can cause a significant negative impact on an individual’s quality of life if left untreated.1,2 In a meeting held at University Malaya Medical Centre, Associate Professor Dr Ong Teng Aik shared his insights on the management of nocturia.

Refining the role of combination therapy for the medical management of benign prostatic hyperplasia

15 Jun 2017

At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).

Research sheds light on PARP inhibitor use in mCRPC

Jackey Suen, 06 Mar 2019

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Immune-checkpoint inhibitors changing the landscape of bladder cancer management

Dr. Joseph Delano Fule Robles, 04 Mar 2019

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Robot-assisted radical cystectomy comparable to open cystectomy for urologic cancers

Dr. Joseph Delano Fule Robles, 22 Feb 2019

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Nanotechnology structured water shows potential for ED treatment

Audrey Abella, 11 May 2018

Nanotechnology structured water was similarly effective as tadalafil in improving erectile function, suggesting that it could be a potential treatment option for erectile dysfunction (ED), according to a study presented at EAU held in Copenhagen, Denmark.

Vibegron shows potential as OAB treatment

Audrey Abella, 30 Apr 2018

The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.

No benefit to targeted antibiotic prophylaxis before TRUS-guided prostate biopsy

Roshini Claire Anthony, 23 Apr 2018

Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.